Hualan Biological Bacterin Inc.

Shenzhen Stock Exchange 301207.SZ

Hualan Biological Bacterin Inc. Gross Profit Margin for the year ending December 31, 2023: 88.09%

Hualan Biological Bacterin Inc. Gross Profit Margin is 88.09% for the year ending December 31, 2023, a 0.00% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Hualan Biological Bacterin Inc. Gross Profit Margin for the year ending December 31, 2022 was 88.09%, a 0.17% change year over year.
  • Hualan Biological Bacterin Inc. Gross Profit Margin for the year ending December 31, 2021 was 87.94%, a -1.60% change year over year.
  • Hualan Biological Bacterin Inc. Gross Profit Margin for the year ending December 31, 2020 was 89.37%, a 5.57% change year over year.
  • Hualan Biological Bacterin Inc. Gross Profit Margin for the year ending December 31, 2019 was 84.65%, a 0.54% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
SV Wall Street
Shenzhen Stock Exchange: 301207.SZ

Hualan Biological Bacterin Inc.

CEO Ms. Wenjue An
IPO Date Feb. 18, 2022
Location China
Headquarters No. 1, Westlands Road
Employees 770
Sector Healthcare
Industries
Vaccines Biotechnology
Description

Hualan Biological Bacterin Inc. engages in the research, development, production, and sale of vaccines in China. It offers It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, H1N1 influenza virus split vaccines, ACYW135 meningococcal polysaccharide plague vaccines, recombinant hepatitis B vaccines, and group A and C meningococcal polysaccharide vaccines, as well as genetic engineering vaccines for human use. The company was founded in 2005 and is based in Xinxiang, China. Hualan Biological Bacterin Inc. was formerly a subsidiary of Hualan Biological Engineering Inc.

StockViz Staff

February 2, 2025

Any question? Send us an email